Page 35 - GALENIKA MEDICAL JOURNAL

N, et al. Thalamic pain: anatomical and physiological indices of 36. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of
prediction. Brain. 2016 Mar;139(Pt 3):708-22. pregabalin in neuropathic pain evaluated in a 12-week, randomised,
double-blind, multicentre, placebo-controlled trial of flexible- and fixed-
27. Finnerup NB, Jensen MP, Norrbrink C, Trok K, Johannesen IL, Jensen dose regimens. Pain. 2005 Jun;115(3):254-63.
TS, et al. A prospective study of pain and psychological functioning
following traumatic spinal cord injury. Spinal Cord. 2016 Oct;54(10):816- 37. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin
21. for relief of neuropathic pain associated with diabetic neuropathy: a
randomized, double-blind study. Eur J Pain. 2008 Feb;12(2):203-13.
28. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis--
prevalence and clinical characteristics. Eur J Pain. 2005 Oct;9(5):531-42. 38. Mu Y, Liu X, Li Q, Chen K, Liu Y, Lv X, et al. Efficacy and safety of
pregabalin for painful diabetic peripheral neuropathy in a population
29. Gillving M, Demant D, Holbech JV, Gylfadottir SS, Bach FW, Jensen of Chinese patients: A randomized placebo-controlled trial. J Diabetes.
TS, et al. A randomized, controlled trial of a β2-agonist in painful 2018 Mar;10(3):256-65.
polyneuropathy. Pain. 2021 May 1;162(5):1364-73.
39. Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, et al. Gabapentin
30. Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The for chronic neuropathic pain in adults. Cochrane Database Syst Rev.
neuropathic pain: An overview of the current treatment and future 2017 Jun 9;6(6):CD007938.
therapeutic approaches. Int J Immunopathol Pharmacol. 2019 Jan-
Dec;33:2058738419838383. 40. Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical
guide. Pract Neurol. 2021 Oct;21(5):392-402.
31. Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropathic Pain with
Venlafaxine: A Systematic Review. Pain Med. 2017 Oct 1;18(10):1999- 41. Liampas A, Velidakis N, Georgiou T, Vadalouca A, Varrassi G,
2012. Hadjigeorgiou GM, et al. Prevalence and Management Challenges in
Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-
32. Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanás T. A analysis. Adv Ther. 2020 Jul;37(7):3278-91.
Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine.
Front Psychiatry. 2020 Oct 23;11:554899. 42. Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic Approaches for
Peripheral and Central Neuropathic Pain. Behav Neurol. 2019 Nov
33. Andruszkiewicz R, Silverman RB. 4-Amino-3-alkylbutanoic acids as 21;2019:8685954.
substrates for gamma-aminobutyric acid aminotransferase. J Biol
Chem. 1990 Dec 25;265(36):22288-91.
34. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, et al. Pregabalin is Konflikt interesa: Nema
a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel
subunits. Eur J Pharmacol. 2011 Sep 30;667(1-3):80-90. Primljeno: 07. 04. 2024.
35. Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, Prihvaćeno: 12. 05. 2024.
et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Onlajn: 01. 06. 2024.
Clin Pharmacol. 2010 Aug;50(8):941-50.

REVIJALNI RADOVI Galenika Medical Journal, 2024; 3(10):28-33. 33